These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 32633947)

  • 1. Integrating the Impact of Lipophilicity on Potency and Pharmacokinetic Parameters Enables the Use of Diverse Chemical Space during Small Molecule Drug Optimization.
    Miller RR; Madeira M; Wood HB; Geissler WM; Raab CE; Martin IJ
    J Med Chem; 2020 Nov; 63(21):12156-12170. PubMed ID: 32633947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety.
    Meanwell NA
    Chem Res Toxicol; 2011 Sep; 24(9):1420-56. PubMed ID: 21790149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-based druggability assessment--identifying suitable targets for small molecule therapeutics.
    Fauman EB; Rai BK; Huang ES
    Curr Opin Chem Biol; 2011 Aug; 15(4):463-8. PubMed ID: 21704549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strategies to optimize drug half-life in lead candidate identification.
    Broccatelli F; E C A Hop C; Wright M
    Expert Opin Drug Discov; 2019 Mar; 14(3):221-230. PubMed ID: 30675823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The influence of lipophilicity in drug discovery and design.
    Arnott JA; Planey SL
    Expert Opin Drug Discov; 2012 Oct; 7(10):863-75. PubMed ID: 22992175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of physicochemical and molecular properties in drug design: navigation in the "drug-like" chemical space.
    Vallianatou T; Giaginis C; Tsantili-Kakoulidou A
    Adv Exp Med Biol; 2015; 822():187-94. PubMed ID: 25416989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Do we need to optimize plasma protein and tissue binding in drug discovery?
    Liu X; Chen C; Hop CE
    Curr Top Med Chem; 2011; 11(4):450-66. PubMed ID: 21320069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A BOILED-Egg To Predict Gastrointestinal Absorption and Brain Penetration of Small Molecules.
    Daina A; Zoete V
    ChemMedChem; 2016 Jun; 11(11):1117-21. PubMed ID: 27218427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipophilic Permeability Efficiency Reconciles the Opposing Roles of Lipophilicity in Membrane Permeability and Aqueous Solubility.
    Naylor MR; Ly AM; Handford MJ; Ramos DP; Pye CR; Furukawa A; Klein VG; Noland RP; Edmondson Q; Turmon AC; Hewitt WM; Schwochert J; Townsend CE; Kelly CN; Blanco MJ; Lokey RS
    J Med Chem; 2018 Dec; 61(24):11169-11182. PubMed ID: 30395703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug Distribution Part 2. Predicting Volume of Distribution from Plasma Protein Binding and Membrane Partitioning.
    Korzekwa K; Nagar S
    Pharm Res; 2017 Mar; 34(3):544-551. PubMed ID: 27966088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving Drug Design: An Update on Recent Applications of Efficiency Metrics, Strategies for Replacing Problematic Elements, and Compounds in Nontraditional Drug Space.
    Meanwell NA
    Chem Res Toxicol; 2016 Apr; 29(4):564-616. PubMed ID: 26974882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipophilicity--methods of determination and its role in medicinal chemistry.
    Rutkowska E; Pajak K; Jóźwiak K
    Acta Pol Pharm; 2013; 70(1):3-18. PubMed ID: 23610954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of ligand efficiency metrics in drug discovery.
    Hopkins AL; Keserü GM; Leeson PD; Rees DC; Reynolds CH
    Nat Rev Drug Discov; 2014 Feb; 13(2):105-21. PubMed ID: 24481311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Druggable pockets and binding site centric chemical space: a paradigm shift in drug discovery.
    Pérot S; Sperandio O; Miteva MA; Camproux AC; Villoutreix BO
    Drug Discov Today; 2010 Aug; 15(15-16):656-67. PubMed ID: 20685398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipophilicity in drug design: an overview of lipophilicity descriptors in 3D-QSAR studies.
    Ginex T; Vazquez J; Gilbert E; Herrero E; Luque FJ
    Future Med Chem; 2019 May; 11(10):1177-1193. PubMed ID: 30799643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cellular target engagement: a new paradigm in drug discovery.
    Babic I; Kesari S; Nurmemmedov E
    Future Med Chem; 2018 Jul; 10(14):1641-1644. PubMed ID: 29957028
    [No Abstract]   [Full Text] [Related]  

  • 17. [Lead compound optimization strategy (1)--changing metabolic pathways and optimizing metabolism stability].
    Wang J; Liu H
    Yao Xue Xue Bao; 2013 Oct; 48(10):1521-31. PubMed ID: 24417078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The assessment and characterisation of drug plasma protein binding in the body using QSAR.
    Agatonovic-Kustrin S; Morton DW; Yusof PA
    Mini Rev Med Chem; 2014; 14(6):484-93. PubMed ID: 24873821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deep learning approaches in predicting ADMET properties.
    Cáceres EL; Tudor M; Cheng AC
    Future Med Chem; 2020 Nov; 12(22):1995-1999. PubMed ID: 33124448
    [No Abstract]   [Full Text] [Related]  

  • 20. Hydration patterns of rings in drugs and relationship to lipophilicity: A DFT study.
    Haritha M; Suresh CH
    J Comput Chem; 2022 Mar; 43(7):477-490. PubMed ID: 34978337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.